# Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

> **NCT04165993** · PHASE2 · UNKNOWN · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 68 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Concurrent chemotherapy and KN026
- **DRUG:** KN026 monotherapy
- **DRUG:** KN026 combination

## Key facts

- **NCT ID:** NCT04165993
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-31
- **Primary completion:** 2021-05-27
- **Final completion:** 2025-12-31
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04165993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04165993, "Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04165993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*